Survival Outcomes of Lung Adenocarcinoma With Intestinal Differentiation in the Era of Immunotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lung adenocarcinoma with intestinal differentiation (LAID) shows poorer survival outcomes in the immunotherapy era. However, immunotherapy-based treatments may offer improved survival for this rare non-small cell lung cancer subtype.
Area Of Science
- Oncology
- Pulmonology
- Cancer Research
Background
- Lung adenocarcinoma (LUAD) with intestinal differentiation (LAID) is a rare, heterogeneous non-small cell lung cancer (NSCLC) subtype.
- Historically, LAID has been associated with poorer prognosis compared to other LUADs, particularly in the chemotherapy era.
Purpose Of The Study
- To assess the survival outcomes of LAID patients in the current era of immunotherapy.
- To compare the efficacy of different treatment modalities, including immunotherapy, for LAID.
Main Methods
- Utilized the National Cancer Database to identify stage IV adenocarcinoma cases diagnosed between 2016 and 2019.
- Defined LAID based on specific histological subtypes: invasive mucinous, colloid, or enteric adenocarcinoma.
- Employed log-rank tests for unadjusted survival comparisons and Cox multivariable regression for adjusted analyses.
Main Results
- A total of 40,516 patients were analyzed, with 855 diagnosed with LAID.
- Patients with LAID exhibited a significantly higher risk of death (HR=1.31) and shorter median survival (9.19 months) compared to other LUAD subtypes (11.81 months).
- Chemoimmunotherapy demonstrated a median overall survival of 11.16 months for LAID patients, compared to 9.19 months for immunotherapy alone and 7.09 months for chemotherapy alone.
Conclusions
- LAID continues to be associated with poorer survival outcomes in the immunotherapy era compared to other LUAD subtypes.
- Immunotherapy, particularly in combination with chemotherapy, may offer survival benefits for patients with this rare LUAD subtype.
- Further research is warranted to optimize treatment strategies for LAID.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
